;PMID: 1700215
;source_file_1754.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..219] = [t:52..219]
;2)section:[e:223..283] = [t:223..283]
;3)section:[e:287..356] = [t:287..356]
;4)sentence:[e:360..475] = [t:360..475]
;5)sentence:[e:476..683] = [t:476..683]
;6)sentence:[e:684..811] = [t:684..811]
;7)sentence:[e:812..920] = [t:812..920]
;8)sentence:[e:921..1041] = [t:921..1041]
;9)sentence:[e:1042..1120] = [t:1042..1120]
;10)sentence:[e:1121..1276] = [t:1121..1276]
;11)section:[e:1280..1324] = [t:1280..1324]

;section 0 Span:0..46
;J Cardiovasc Pharmacol. 1990 Sep;16(3):438-43.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..12] Cardiovasc) (NNP:[13..22] Pharmacol)
        (.:[22..23] .) (CD:[24..28] 1990) (CC:[29..35] Sep;16)
        (-LRB-:[35..36] -LRB-) (CD:[36..37] 3) (-RRB-:[37..38] -RRB-)
        (CD:[38..45] :438-43) (.:[45..46] .)))

;sentence 1 Span:52..219
;Cytochrome P450-dependent arachidonic acid metabolites, 19- and 
;20-hydroxyeicosatetraenoic acids, enhance sodium-potassium ATPase activity in
; vascular smooth muscle.
;[52..67]:cyp450:"Cytochrome P450"
;[78..106]:substance:"arachidonic acid metabolites"
;[108..111]...[120..149]:substance:"19-"..."hydroxyeicosatetraenoic acids"
;[117..149]:substance:"20-hydroxyeicosatetraenoic acids"
;[159..182]:substance:"sodium-potassium ATPase"
(SENT
  (S-HLN
    (NP-SBJ
      (NP
        (ADJP
          (NML (NN:[52..62] Cytochrome) (NN:[63..67] P450))
          (HYPH:[67..68] -) (JJ:[68..77] dependent))
        
        (NML (JJ:[78..89] arachidonic) (NN:[90..94] acid))
        (NNS:[95..106] metabolites))
      (,:[106..107] ,)
      (NP
        (NP
          (ADJP (CD:[108..110] 19) (HYPH:[110..111] -)
            (ADJP-1 (-NONE-:[111..111] *P*)))
          (NML-2 (-NONE-:[111..111] *P*)))
        (CC:[112..115] and)
        (NP
          (ADJP (CD:[117..119] 20) (HYPH:[119..120] -)
            (ADJP-1 (JJ:[120..143] hydroxyeicosatetraenoic)))
          (NML-2 (NNS:[144..149] acids)))))
    (,:[149..150] ,)
    (VP (VBP:[151..158] enhance)
      (NP
        
        (NML (NN:[159..165] sodium) (HYPH:[165..166] -)
             (NN:[166..175] potassium))
        (NN:[176..182] ATPase)
        (NN:[183..191] activity))
      (PP-LOC (IN:[192..194] in)
        (NP (JJ:[196..204] vascular) (JJ:[205..211] smooth)
            (NN:[212..218] muscle))))
    (.:[218..219] .)))

;section 2 Span:223..283
;Escalante B, Sessa WC, Falck JR, Yadagiri P, Schwartzman ML.
(SEC
  (FRAG (NNP:[223..232] Escalante) (NNP:[233..234] B) (,:[234..235] ,)
        (NNP:[236..241] Sessa) (NNP:[242..244] WC) (,:[244..245] ,)
        (NNP:[246..251] Falck) (NNP:[252..254] JR) (,:[254..255] ,)
        (NNP:[256..264] Yadagiri) (NNP:[265..267] P,)
        (NNP:[268..279] Schwartzman) (NNP:[280..282] ML) (.:[282..283] .)))

;section 3 Span:287..356
;Department of Pharmacology, New York Medical College, Valhalla 10595.
(SEC
  (FRAG (NNP:[287..297] Department) (IN:[298..300] of)
        (NNP:[301..313] Pharmacology) (,:[313..314] ,) (NNP:[315..318] New)
        (NNP:[319..323] York) (NNP:[324..331] Medical) (NNP:[332..339] College)
        (,:[339..340] ,) (NNP:[341..349] Valhalla) (CD:[350..355] 10595)
        (.:[355..356] .)))

;sentence 4 Span:360..475
;Several cytochrome P450-dependent arachidonic acid metabolites have been
;shown  to affect Na+,K(+)-ATPase activity.
;[368..383]:cyp450:"cytochrome P450"
;[394..422]:substance:"arachidonic acid metabolites"
;[450..465]:substance:"Na+,K(+)-ATPase"
(SENT
  (S
    (NP-SBJ-1 (JJ:[360..367] Several)
      (ADJP
        (NML (NN:[368..378] cytochrome) (NN:[379..383] P450))
        (HYPH:[383..384] -) (JJ:[384..393] dependent))
      
      (NML (JJ:[394..405] arachidonic) (NN:[406..410] acid))
      (NNS:[411..422] metabolites))
    (VP (VBP:[423..427] have)
      (VP (VBN:[428..432] been)
        (VP (VBN:[433..438] shown)
          (S
            (NP-SBJ-1 (-NONE-:[438..438] *))
            (VP (TO:[440..442] to)
              (VP (VB:[443..449] affect)
                (NP (NN:[450..465] Na+,K-LRB-+-RRB--ATPase)
                    (NN:[466..474] activity))))))))
    (.:[474..475] .)))

;sentence 5 Span:476..683
;In the present study, we tested the effect  of omega- and omega -
;1-hydroxylated products, i.e., 19- and  20-hydroxyeicosatetraenoic acids (19-
;and 20-HETE), on the K-induced relaxation  in rat aortic rings.
;[557..565]:substance:"products"
;[573..576]...[585..614]:substance:"19-"..."hydroxyeicosatetraenoic acids"
;[582..614]:substance:"20-hydroxyeicosatetraenoic acids"
;[616..619]...[627..631]:substance:"19-"..."HETE"
;[624..631]:substance:"20-HETE"
;[641..642]:substance:"K"
(SENT
  (S
    (PP-LOC (IN:[476..478] In)
      (NP (DT:[479..482] the) (JJ:[483..490] present) (NN:[491..496] study)))
    (,:[496..497] ,)
    (NP-SBJ (PRP:[498..500] we))
    (VP (VBD:[501..507] tested)
      (NP
        (NP (DT:[508..511] the) (NN:[512..518] effect))
        (PP (IN:[520..522] of)
          (NP
            (NP
              (NP
                (ADJP (SYM:[523..528] omega) (HYPH:[528..529] -)
                  (ADJP-4 (-NONE-:[529..529] *P*)))
                (NML-5 (-NONE-:[529..529] *P*)))
              (CC:[530..533] and)
              (NP
                (ADJP (SYM:[534..539] omega) (HYPH:[540..541] -)
                      (CD:[542..543] 1) (HYPH:[543..544] -)
                  (ADJP-4 (VBN:[544..556] hydroxylated)))
                (NML-5 (NNS:[557..565] products))))
            (,:[565..566] ,)
            (NP
              (ADVP (FW:[567..571] i.e.))
              (,:[571..572] ,)
              (NP
                (NP
                  (NP
                    (ADJP (CD:[573..575] 19) (HYPH:[575..576] -)
                      (ADJP-2 (-NONE-:[576..576] *P*)))
                    (NML-3 (-NONE-:[576..576] *P*)))
                  (CC:[577..580] and)
                  (NP
                    (ADJP (CD:[582..584] 20) (HYPH:[584..585] -)
                      (ADJP-2 (JJ:[585..608] hydroxyeicosatetraenoic)))
                    (NML-3 (NNS:[609..614] acids))))
                (NP (-LRB-:[615..616] -LRB-)
                  (NP (CD:[616..618] 19) (HYPH:[618..619] -)
                    (NML-1 (-NONE-:[619..619] *P*)))
                  (CC:[620..623] and)
                  (NP (CD:[624..626] 20) (HYPH:[626..627] -)
                    (NML-1 (NN:[627..631] HETE)))
                  (-RRB-:[631..632] -RRB-))))))
        (,:[632..633] ,)
        (PP (IN:[634..636] on)
          (NP
            (NP (DT:[637..640] the)
              (ADJP (NN:[641..642] K) (HYPH:[642..643] -)
                    (VBN:[643..650] induced))
              (NN:[651..661] relaxation))
            (PP-LOC (IN:[663..665] in)
              (NP (NN:[666..669] rat) (JJ:[670..676] aortic)
                  (NNS:[677..682] rings)))))))
    (.:[682..683] .)))

;sentence 6 Span:684..811
;19-HETE and 20-HETE increased the magnitude of the  potassium-induced
;relaxation in a dose-dependent fashion (10(-7)-10(-5) M).
;[684..691]:substance:"19-HETE"
;[696..703]:substance:"20-HETE"
;[736..745]:substance:"potassium"
;[794..807]:quantitative-value:"10(-7)-10(-5)"
;[808..809]:quantitative-units:"M"
(SENT
  (S
    (NP-SBJ (NN:[684..691] 19-HETE) (CC:[692..695] and) (NN:[696..703] 20-HETE))
    (VP (VBD:[704..713] increased)
      (NP
        (NP (DT:[714..717] the) (NN:[718..727] magnitude))
        (PP (IN:[728..730] of)
          (NP (DT:[731..734] the)
            (ADJP (NN:[736..745] potassium) (HYPH:[745..746] -)
                  (VBN:[746..753] induced))
            (NN:[754..764] relaxation))))
      (PP-MNR (IN:[765..767] in)
        (NP (DT:[768..769] a)
          (ADJP (NN:[770..774] dose) (HYPH:[774..775] -)
                (JJ:[775..784] dependent))
          (NN:[785..792] fashion)))
      (PRN (-LRB-:[793..794] -LRB-)
        (PRN
          (QP (CD:[794..800] 10-LRB--7-RRB-) (HYPH:[800..801] -)
              (CD:[801..807] 10-LRB--5-RRB-))
          (NN:[808..809] M))
        (-RRB-:[809..810] -RRB-)))
    (.:[810..811] .)))

;sentence 7 Span:812..920
;The  inhibitory effect of ouabain on the potassium-induced relaxation was
;reversed by  both 19- and 20-HETE.
;[838..845]:substance:"ouabain"
;[853..862]:substance:"potassium"
;[904..907]...[915..919]:substance:"19-"..."HETE"
;[912..919]:substance:"20-HETE"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[812..815] The) (JJ:[817..827] inhibitory) (NN:[828..834] effect))
      (PP (IN:[835..837] of)
        (NP (NN:[838..845] ouabain)))
      (PP (IN:[846..848] on)
        (NP (DT:[849..852] the)
          (ADJP (NN:[853..862] potassium) (HYPH:[862..863] -)
                (VBN:[863..870] induced))
          (NN:[871..881] relaxation))))
    (VP (VBD:[882..885] was)
      (VP (VBN:[886..894] reversed)
        (NP-2 (-NONE-:[894..894] *))
        (PP (IN:[895..897] by)
          (NP-LGS (CC:[899..903] both)
            (NML (CD:[904..906] 19) (HYPH:[906..907] -)
              (NML-1 (-NONE-:[907..907] *P*)))
            (CC:[908..911] and)
            (NML (CD:[912..914] 20) (HYPH:[914..915] -)
              (NML-1 (NN:[915..919] HETE)))))))
    (.:[919..920] .)))

;sentence 8 Span:921..1041
;In addition, indomethacin fully inhibited the stimulatory  effect of 19- and
;20-HETE on relaxation induced by potassium.
;[934..946]:substance:"indomethacin"
;[990..993]...[1001..1005]:substance:"19-"..."HETE"
;[998..1005]:substance:"20-HETE"
;[1031..1040]:substance:"potassium"
(SENT
  (S
    (PP (IN:[921..923] In)
      (NP (NN:[924..932] addition)))
    (,:[932..933] ,)
    (NP-SBJ (NN:[934..946] indomethacin))
    (ADVP (RB:[947..952] fully))
    (VP (VBD:[953..962] inhibited)
      (NP
        (NP (DT:[963..966] the) (JJ:[967..978] stimulatory)
            (NN:[980..986] effect))
        (PP (IN:[987..989] of)
          (NP
            (NP (CD:[990..992] 19) (HYPH:[992..993] -)
              (NML-1 (-NONE-:[993..993] *P*)))
            (CC:[994..997] and)
            (NP (CD:[998..1000] 20) (HYPH:[1000..1001] -)
              (NML-1 (NN:[1001..1005] HETE)))))
        (PP (IN:[1006..1008] on)
          (NP
            (NP (NN:[1009..1019] relaxation))
            (VP (VBN:[1020..1027] induced)
              (NP (-NONE-:[1027..1027] *))
              (PP (IN:[1028..1030] by)
                (NP-LGS (NN:[1031..1040] potassium))))))))
    (.:[1040..1041] .)))

;sentence 9 Span:1042..1120
;Vascular  ouabain-sensitive 86Rb uptake was also increased by 19- and
;20-HETE.
;[1052..1059]:substance:"ouabain"
;[1070..1074]:substance:"86Rb"
;[1104..1107]...[1115..1119]:substance:"19-"..."HETE"
;[1112..1119]:substance:"20-HETE"
(SENT
  (S
    (NP-SBJ-2 (JJ:[1042..1050] Vascular)
      (ADJP (NN:[1052..1059] ouabain) (HYPH:[1059..1060] -)
            (JJ:[1060..1069] sensitive))
      (NN:[1070..1074] 86Rb) (NN:[1075..1081] uptake))
    (VP (VBD:[1082..1085] was)
      (ADVP (RB:[1086..1090] also))
      (VP (VBN:[1091..1100] increased)
        (NP-2 (-NONE-:[1100..1100] *))
        (PP (IN:[1101..1103] by)
          (NP-LGS
            (NP (CD:[1104..1106] 19) (HYPH:[1106..1107] -)
              (NML-1 (-NONE-:[1107..1107] *P*)))
            (CC:[1108..1111] and)
            (NP (CD:[1112..1114] 20) (HYPH:[1114..1115] -)
              (NML-1 (NN:[1115..1119] HETE)))))))
    (.:[1119..1120] .)))

;sentence 10 Span:1121..1276
;These  observations suggest that 19- and 20-HETE stimulate vascular
;Na+,K(+)-ATPase via  their conversion by cyclooxygenase to prostaglandin-like
;material.
;[1154..1157]...[1165..1169]:substance:"19-"..."HETE"
;[1162..1169]:substance:"20-HETE"
;[1189..1204]:substance:"Na+,K(+)-ATPase"
;[1230..1244]:substance:"cyclooxygenase"
;[1248..1261]:substance:"prostaglandin"
(SENT
  (S
    (NP-SBJ (DT:[1121..1126] These) (NNS:[1128..1140] observations))
    (VP (VBP:[1141..1148] suggest)
      (SBAR (IN:[1149..1153] that)
        (S
          (NP-SBJ
            (NP (CD:[1154..1156] 19) (HYPH:[1156..1157] -)
              (NML-1 (-NONE-:[1157..1157] *P*)))
            (CC:[1158..1161] and)
            (NP (CD:[1162..1164] 20) (HYPH:[1164..1165] -)
              (NML-1 (NN:[1165..1169] HETE))))
          (VP (VBP:[1170..1179] stimulate)
            (NP (JJ:[1180..1188] vascular)
                (NN:[1189..1204] Na+,K-LRB-+-RRB--ATPase))
            (PP-MNR (IN:[1205..1208] via)
              (NP
                (NP (PRP$:[1210..1215] their) (NN:[1216..1226] conversion))
                (PP (IN:[1227..1229] by)
                  (NP (NN:[1230..1244] cyclooxygenase)))
                (PP (TO:[1245..1247] to)
                  (NP
                    (ADJP (NN:[1248..1261] prostaglandin) (HYPH:[1261..1262] -)
                          (JJ:[1262..1266] like))
                    (NN:[1267..1275] material)))))))))
    (.:[1275..1276] .)))

;section 11 Span:1280..1324
;PMID: 1700215 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1280..1284] PMID) (::[1284..1285] :) (CD:[1286..1293] 1700215)
        (NN:[1294..1295] -LSB-) (NNP:[1295..1301] PubMed) (::[1302..1303] -)
        (NN:[1304..1311] indexed) (IN:[1312..1315] for)
        (NNP:[1316..1324] MEDLINE-RSB-)))
